USANA Health Sciences, Inc. (USNA) CFO G Doug Iiekking Sells 6,570 Shares of Stock

Share on StockTwits

USANA Health Sciences, Inc. (NYSE:USNA) CFO G Doug Iiekking sold 6,570 shares of the stock in a transaction dated Thursday, September 6th. The stock was sold at an average price of $126.25, for a total transaction of $829,462.50. Following the completion of the sale, the chief financial officer now directly owns 2,200 shares in the company, valued at approximately $277,750. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

G Doug Iiekking also recently made the following trade(s):

  • On Tuesday, September 4th, G Doug Iiekking sold 2,200 shares of USANA Health Sciences stock. The stock was sold at an average price of $130.08, for a total transaction of $286,176.00.

Shares of USNA stock traded up $0.15 during trading hours on Friday, reaching $124.75. The stock had a trading volume of 4,281 shares, compared to its average volume of 128,237. USANA Health Sciences, Inc. has a twelve month low of $55.50 and a twelve month high of $137.95. The stock has a market cap of $3.05 billion, a PE ratio of 30.74 and a beta of 0.64.

USANA Health Sciences (NYSE:USNA) last released its quarterly earnings data on Tuesday, July 24th. The company reported $1.36 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.11 by $0.25. USANA Health Sciences had a net margin of 7.16% and a return on equity of 29.50%. The business had revenue of $301.50 million for the quarter, compared to analysts’ expectations of $278.41 million. During the same quarter last year, the company earned $0.98 EPS. The company’s revenue for the quarter was up 17.3% compared to the same quarter last year. analysts expect that USANA Health Sciences, Inc. will post 4.9 earnings per share for the current fiscal year.

Separately, Pivotal Research reaffirmed a “hold” rating and issued a $135.00 price objective on shares of USANA Health Sciences in a report on Wednesday, July 25th. One research analyst has rated the stock with a sell rating, two have given a hold rating and one has issued a buy rating to the stock. USANA Health Sciences has a consensus rating of “Hold” and a consensus price target of $135.00.

A number of institutional investors have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp increased its stake in USANA Health Sciences by 22.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 112,111 shares of the company’s stock valued at $12,926,000 after buying an additional 20,510 shares during the period. Public Employees Retirement System of Ohio increased its stake in USANA Health Sciences by 36.1% during the 2nd quarter. Public Employees Retirement System of Ohio now owns 15,138 shares of the company’s stock valued at $1,745,000 after buying an additional 4,013 shares during the period. WINTON GROUP Ltd grew its stake in shares of USANA Health Sciences by 9.5% in the 2nd quarter. WINTON GROUP Ltd now owns 8,425 shares of the company’s stock worth $971,000 after purchasing an additional 733 shares during the last quarter. Nomura Holdings Inc. acquired a new position in shares of USANA Health Sciences in the 2nd quarter worth approximately $250,000. Finally, California Public Employees Retirement System grew its stake in shares of USANA Health Sciences by 6.4% in the 2nd quarter. California Public Employees Retirement System now owns 22,550 shares of the company’s stock worth $2,600,000 after purchasing an additional 1,366 shares during the last quarter. 56.38% of the stock is currently owned by hedge funds and other institutional investors.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include low-glycemic meal replacement shakes, snack bars, and other related products, which provide macro-nutrition.

Further Reading: Price to Earnings Ratio (PE), For Valuing Stocks

Insider Buying and Selling by Quarter for USANA Health Sciences (NYSE:USNA)

Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply